| Identification | Back Directory | [Name]
ASTRESSIN | [CAS]
170809-51-5 | [Synonyms]
ASTRESSIN
ASTRESSIN (HUMAN, RAT)
Astressin >=90% (HPLC)
M.W. 3563.24 C161H269N49O42
ASTRESSIN TRIFLUOROACETATE SALT
[D-PHE12, NLE21,38, GLU30, LYS33]-CRF (12-41) (HUMAN, RAT)
[D-PHE12, NLE21,38, GLU30, LYS33]-CRF (12-41), CYCLIC LACTAM, HUMAN, RAT
[D-PHE12,NLE21,38,GLU30,LYS33]-CORTICOTROPIN RELEASING FACTOR FRAGMENT 12-41
(D-PHE12,NLE21,38,GLU30,LYS33)-CRF (12-41) (HUMAN, RAT) TRIFLUOROACETATE SALT
[D-PHE12, NLE21,38, GLU30, LYS33]-CORTICOTROPIN RELEASING FACTOR (12-41) (HUMAN, RAT)
(D-PHE12,NLE21,38,GLU30,LYS33)-CRF (12-41)(HUMAN, RAT) (CYCLIZED BETWEEN GAMMA-GLU30 ANDEPSILON-LYS33)
DPHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2
D-PHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2
H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2
H-D-PHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-CYCLO(-GAMMA-GLU-ALA-HIS-EPSILON-LYS)-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2
D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 (LactaM bridge Glu30-Lys33)
Astressin trifluoroacetate salt H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 trifluoroacetate salt
L-Isoleucinamide, D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-α-glutamyl-L-alanyl-L-histidyl-L-lysyl-L-asparaginyl-L-arginyl-L-lysyl-L-leucyl-L-norl... | [EINECS(EC#)]
617-559-7 | [Molecular Formula]
C161H269N49O42 | [MDL Number]
MFCD00798715 | [MOL File]
170809-51-5.mol | [Molecular Weight]
3563.16 |
| Chemical Properties | Back Directory | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
H2OPeptide Solubility and Storage Guidelines:1.??Calculate the length of the peptide.2.??Calculate the overall charge of the entire peptide according to the following table:3.??Recommended solution: | [form ]
Powder | [color ]
White to off-white | [Water Solubility ]
Soluble to 1 mg/ml in 10% Acetic acid / water | [Sequence]
H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 |
| Hazard Information | Back Directory | [Uses]
Astressin has been used as a CRF-receptor antagonist to study its effects on the decrease in the Schaffer collateral-CA1 field potential induced by hypoxia/hypoglycemia (ischemia) in rat hippocampal slices. | [Definition]
ChEBI: A 30-membered homodetic cyclic peptide comprising the sequence D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 cyclised by an amide bridge,
ormed by condensation of the side-chain carboxy group of the Glu residue at position 19 and the side-chain amino group of the Lys residue at position 22. | [Biochem/physiol Actions]
Astressin is a non-selective corticotropin releasing factor (CRF)-receptor antagonist. It potentially blocks CRF-induced adrenocorticotropic hormone (ACTH) release. Astressin effectively deceases delayed effects of chronic social isolation such as anxiety and fobial states in rats. | [Enzyme inhibitor]
This novel CRF antagonist (MW = 3663.20 g/mol; CAS 170809-51-5; Sequence: D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala- Glu-Gln-Ala-Gln-cyclo-(g-Glu-Ala-His-e-Lys)Asn-Arg-Leu-Leu-Mle-Glu- Ile-Ile-NH2; Solubility: 1 mg/mL in Acetic acid/water (10% vol/vol); Alternate Name: [D-Phe 12 , Nle 21,38 , Glu30 , Lys 33 ]-CRF) targets human Corticotropin-Releasing hormone (CRH) Receptor subtypes CRF2α (Ki = 1.5 nM) and CRF2β (Ki = 1 nM), with a comparable value (2 nM) for CRF1. (See also Antisauvagine-30; K41448) These type-2 GPCRs reside in plasma membranes of hormone-sensitive cells and bind CRH, a peptide hormone and neurotransmitter involved in stress responses. Astressin is a structurally constrained and competitive antagonists of corticotropin- releasing factor. Astressin is neuroprotective in the hippocampus when administered after a seizure. Peripheral injection of astressin blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats. A related antagonist is Astressin 2B (FW = 4041.69 g/mol; CAS 681260-70-8; Sequence: Ac-Asp-Leu-Ser-D-Phe-His-a-methyl-Leu-Leu- Arg-Lys-Nle-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala- cyclo-(g-Glu-Ala-Asn-e-Lys)Leu-Leu-Leu-Asp-a-methyl-Leu-Ile-NH2). Astressin 2B is a potent and selective antagonist of CRF2 (IC50 = 1.3 nM) and CRF1 (IC50 > 500 nM). | [storage]
Store at -20°C |
|
|